Adhezion Biomedical LLC, a privately held medical device company based in Wyomissing, announced it completed a long-term agreement with Pfizer Inc. for the exclusive distribution rights of Adhezion’s high-strength topical skin adhesives in the United States and its territories and possessions.
The products include SurgiSeal, SurgiSeal Stylus and SurgiSeal Twist line containing 2-octyl cyanoacrylate, which are used for topical wound closure as an alternative to sutures.
SurgiSeal is intended for topical applications only to hold closed easily approximated skin edges of wounds from surgical incisions, including punctures from minimally invasive surgery and simple, thoroughly cleansed trauma-induced lacerations, according to a news release.
SurgiSeal may be used in conjunction with, but not in place of, deep dermal sutures, it said.
Pete Molinaro, chairman and CEO of Adhezion Biomedical, said the partnership with Pfizer “offers strong support for our business.”
Founded in 2001, Adhezion Biomedical develops and manufactures medical cyanoacrylate products used in the treatment of wound closure, wound management, intravenous device securement and infection prevention. The company has a manufacturing and research facility in Hudson, N.C.